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Feed-based metaphylaxis programs did not affect health or performance of highrisk calves mass medicated with Draxxin on arrival
Abstract
Bovine respiratory disease continues to be the most costly disease affecting productivity and profitability
in the stocker segment. Despite their high cost, longer-acting, injectable therapeutic antimicrobials such
as Draxxin (Tulathromycin; Pfizer Animal Health, New York, NY) can extend the window of treatment
duration, thereby reducing the incidence and severity of bovine respiratory disease. Use of feed-based
metaphylaxis programs, such as therapeutic administration of multiple 5-day pulses of Aureomycin
(αrma, Inc., Bridgewater, NJ), in conjunction with an injectable metaphylaxis program may be a costeffective way to improve bovine respiratory disease therapy without having to physically handle and
stress cattle.
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Feed-Based Metaphylaxis Programs Did Not
Affect Health or Performance of High-Risk
Calves Mass Medicated with Draxxin on Arrival
D.A Blasi, M P. Epp, and R. Derstein

Introduction

Bovine respiratory disease continues to be the most costly disease affecting productivity
and profitability in the stocker segment. Despite their high cost, longer-acting, injectable therapeutic antimicrobials such as Draxxin (Tulathromycin; Pfizer Animal Health,
New York, NY) can extend the window of treatment duration, thereby reducing the
incidence and severity of bovine respiratory disease. Use of feed-based metaphylaxis
programs, such as therapeutic administration of multiple 5-day pulses of Aureomycin
(Alpharma, Inc., Bridgewater, NJ), in conjunction with an injectable metaphylaxis
program may be a cost-effective way to improve bovine respiratory disease therapy without having to physically handle and stress cattle.

Experimental Procedures

One 55-day receiving study was conducted at the Kansas State University Beef Stocker
Unit during May 2008 to determine the response of high-risk stocker calves to concurrent metaphylaxis with Draxxin and Aureomycin. All cattle were sourced from an order
buyer in Tennessee, and cattle were received over 3 consecutive days. Upon arrival,
all calves were weighed, tagged, mass medicated with Draxxin (1.1 mL/100 lb), and
palpated for gender (bull or steer). Calves were then given free-choice access to longstem prairie hay and water. The following day, calves were vaccinated against clostridial
and respiratory diseases and dewormed, and bulls were surgically castrated. Each load
(three total) was then blocked by arrival date and randomly assigned to one of three
treatments for a total of 24 pens. Castrated bulls were distributed equally among the
eight pens within each alley. Cattle were weighed and revaccinated 12 days after initial
processing and weighed again following the 55-day feeding period. Calves were stepped
up using three sequential growing diets ranging from 29% to 36.5% concentrate. Diets
were fed with addition of one of the following three treatments: (1) no top-dress pellets
(control); (2) top-dressed with Aureomycin-containing pellets (10 mg chlortetracycline
per pound of body weight) on days 8 to 12, 14 to 18, 20 to 24, and 26 to 30 post-arrival;
or (3) top-dressed with Aureomycin pellets on days 0 to 4, 6 to 10, 12 to 16, 18 to 22,
and 24 to 28 followed by 25 days of administration of AS-700 (Alpharma, Inc.), which
provided 350 mg/head per day of both chlortetracycline and sulfamethazine. All treatments received Bovatec (Alpharma, Inc.) at 250 to 300 mg/head daily in the complete
feed for the first 28 days on study. The control and Aureomycin-only treatments
received Bovatec from day 29 until conclusion of the study.
Cattle were observed daily for signs of illness and injury by personnel blinded to treatments. Calves were treated for respiratory disease with Draxxin only after a moratorium
of 5 days post-metaphylaxis. Calves determined to need treatment were given Baytril
(Bayer Animal Health, Shawnee Mission, KS) at 5 mL/100 lb body weight as a first
treatment; Nuflor (Intervet/Schering-Plough Animal Health, Millsboro, DE) at
26

Management

6 mL/100 lb body weight as a second treatment, if needed; and Bio-Mycin 200 (Boehringer Ingelheim, Ridgefield, CT) at 4.5 mL/100 lb body weight as a third treatment,
if needed.
Bunks were checked twice daily, and feed was delivered in amounts sufficient to result
in slick bunks both morning and afternoon. Calves were fed their respective diets at
approximately 7:00 a.m. and 3:00 p.m. daily for 55 days.
Daily dry matter intake, gains, and feed efficiencies were determined for each pen
of calves. Health records were used to determine the number of animals treated and
percentage of death loss.
Performance and health data were analyzed by using the random effects MIXED
model procedure SAS (SAS Institute, Inc., Cary, NC). Treatments were arranged in a
randomized incomplete block design; pen served as the experimental unit for growth
and health characteristic analysis. In the model, fixed effects were treatment, lot, and
gender, and random effects were lot × treatment, pen, and animal ID. Percentages of
morbidity and mortality were evaluated by the Chi-Square test, and differences were
declared significant at P<0.05.

Results and Discussion

There were no significant differences among treatments in the percentage of steers
treated once, twice, or one or more times for bovine respiratory disease (P>0.30;
Table 1). There were no significant differences in daily gain (P=0.66), daily dry matter
intake (P=0.68), or feed efficiency (P=0.50) among the three treatments.

Implications

This experiment showed no benefit of feeding Aureomycin for four 5-day periods after
receiving when calves were mass medicated with Draxxin upon arrival. These results
may be beneficial to producers who are evaluating treatment protocols for newly
received high-risk stocker calves.
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Table 1. Treatment incidence for bovine respiratory disease (BRD), percentage of death loss, and growth performance of newly arrived stocker calves receiving injectable and feed-based metaphylaxis programs during a 55-day
receiving study
Treatment1
Draxxin plus
Draxxin plus Aureomycin
Item
Draxxin
Aureomycin plus AS-700
SEM
P-value
No. of pens
8
8
8
No. of steers
32
32
31
No. of castrated bulls
72
73
73
Initial weight, lb
453
449
452
4.0
0.79
Weight at revaccination, lb
507
507
505
5.0
0.97
Final weight, lb
616
613
622
6.0
0.58
Treatments for BRD, % of calves
Treated only once
15.2
22.6
18.8
3.3
0.30
Treated two times or more
24.6
21.2
16.6
4.7
0.49
Total BRD treatment, one or more times
39.8
43.8
35.4
4.8
0.48
Death loss, %
0
0.84
2.18
1.2
0.39
Daily dry matter intake, lb
14.54
14.31
14.68
0.31
0.68
Average daily gain, lb
3.02
3.04
3.15
0.10
0.66
Feed:Gain
4.92
4.81
4.78
0.08
0.50
1
Draxxin, calves administered Draxxin upon arrival; Draxxin plus Aureomycin, calves administered Draxxin upon arrival in addition to pulse dosing
of Aureomycin on days 8 to 12, 14 to 18, 20 to 24, and 26 to 30 post-arrival; Draxxin plus Aureomycin plus AS-700, calves administered Draxxin
upon arrival in addition to pulse dosing of Aureomycin on days 0 to 4, 6 to 10, 12 to 16, 18 to 22, and 24 to 28 followed by 25 days of AS-700.
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